FY2027 Earnings Estimate for FDMT Issued By Leerink Partnrs

Key Points

• Leerink Partners projects 4D Molecular Therapeutics will report an EPS of ($3.10) for FY2027, which is worse than the current consensus estimate of ($2.84) per share.
• 4D Molecular Therapeutics stock recently rose by 6.3%, with its price reaching $6.54, amid significant trading activity.
• Analysts show mixed ratings on the stock, with one "sell," two "hold," and eight "buy" ratings, reflecting a consensus average rating of "Moderate Buy."

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a report issued on Monday, August 11th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings of ($3.10) per share for the year. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

Other equities analysts have also issued reports about the company. Chardan Capital reissued a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. The Goldman Sachs Group cut their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Roth Capital cut their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday. Finally, Barclays lowered their target price on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.40.

4D Molecular Therapeutics Price Performance

FDMT stock traded up $0.01 on Wednesday, reaching $7.27. The company's stock had a trading volume of 1,204,970 shares, compared to its average volume of 885,511. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $17.41. The company has a market capitalization of $339.51 million, a P/E ratio of -2.06 and a beta of 2.83. The firm has a fifty day moving average of $4.68 and a two-hundred day moving average of $4.13.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in 4D Molecular Therapeutics in the fourth quarter worth about $50,000. Velan Capital Investment Management LP bought a new position in 4D Molecular Therapeutics in the fourth quarter valued at approximately $56,000. Virtus ETF Advisers LLC boosted its stake in 4D Molecular Therapeutics by 173.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company's stock valued at $58,000 after acquiring an additional 6,560 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of 4D Molecular Therapeutics during the second quarter worth $42,000. Finally, Los Angeles Capital Management LLC bought a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $42,000. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.